Perspective Therapeutics, Inc. (CATX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Perspective Therapeutics, Inc. (CATX) is up 5.8% since the beginning of the year. At $3 per share, CATX is trading 52.8% below its 52-week high of $6. Investors who bought $1,000 worth of CATX shares 5 years ago would now be looking at an investment worth $416.

Perspective Therapeutics, Inc. (CATX) has returned 5.82% so far this year and -29.88% over the past 12 months. Over the last ten years, CATX has returned -9.03% per year, falling short of the S&P 500 Index benchmark, which averaged 13.07% annually.

Based on dividend-adjusted daily data since Nov 10, 2005, CATX's average daily return is +0.19%, while the average monthly return is +2.66%. At this rate, an investment would double in approximately 2.2 years.

Historically, 40% of months were positive and 60% were negative. The best month was Jan 2021 with a return of +277.8%, while the worst month was Nov 2024 at -63.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 13 months.

On a daily basis, CATX closed higher 42% of trading days. The best single day was Jan 6, 2021 with a return of +167.7%, while the worst single day was Nov 21, 2024 at -51.4%.

Perspective Therapeutics, Inc. has an annualized alpha of 50.01%, beta of 0.80, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 10, 2005.

• This stock participated in 140.06% of S&P 500 Index downside but only 41.45% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CATX ranks 35 for risk / return — below 35% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Perspective Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Perspective Therapeutics, Inc. was 98.18%, occurring on Mar 25, 2009. The portfolio has not yet recovered.

The current Perspective Therapeutics, Inc. drawdown is 96.47%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Perspective Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Perspective Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.